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Objectives. In this B-mode ultrasound study we assessed prav-
astatin treatment effects on carotid and femoral artery walls and
investigated the correlations between the state and evolution of
peripheral and coronary atherosclerosis.
Background. The Regression Growth Evaluation Statin Study
(REGRESS) was an 11-center, 2-year, double-blind, placebo-
controlled, prospective study of 885 men with coronary artery
disease (CAD) (total cholesterol 4 to 8 mmol/liter). The study
primarily investigated pravastatin treatment effects on the coro-
nary lumen. This report focuses on the 255 patients who partici-
pated in the REGRESS ultrasound study.
Methods. Carotid and femoral artery walls were imaged at
baseline and at 6, 12, 18 and 24 months. Pravastatin treatment
effect was defined as the difference in progression of the combined
intima-media thicknesses (IMT) between treatment groups.
Results. Pravastatin treatment effects were highly significant
(combined IMT: p 5 0.0085; combined far wall IMT: p < 0.0001;
common femoral artery far wall IMT: p 5 0.004). Correlations
between the IMTs of the arterial wall segments ranged from 20.17
to 0.81. Baseline correlations between IMT and percent coronary
lumen stenoses ranged from 0.23 to 0.36. Baseline IMT correlated
with the mean coronary segment diameter (r 5 20.32, p 5 0.001)
and minimal coronary obstruction diameter (r 5 20.27, p 5
0.005). There were no individual correlations between IMT and
coronary lumen variables (p > 0.30).
Conclusions. Pravastatin treatment effects on carotid and fem-
oral artery walls were observed. B-mode ultrasound imaging
studies of peripheral arterial walls could not describe the state
and evolution of the coronary lumen in the individual patient, but
proved to be a highly suitable tool for the assessment of antiath-
erosclerotic properties of agents.
(J Am Coll Cardiol 1998;31:1561–7)
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In the in vivo assessment of atherosclerotic change, angiogra-
phy and ultrasound imaging studies are most commonly used.
B-mode ultrasound imaging of carotid and femoral artery walls
allows recognition of the early stages of atherosclerosis (1–3).
Unlike angiography, which investigates the vascular contours
and lumen, B-mode ultrasound imaging depicts the structural
morphology of the arterial wall itself. As shown by Pignoli et al.
(1) in the common carotid artery (CCA) far wall, the leading
edges of the B-mode ultrasound double-line patterns represent
the lumen-intima interface and the media-adventitia interface
of the intima-media complex. Consequently, the distance be-
tween these interfaces is called the intima-media thickness
(IMT). An increase in IMT is regarded as an early sign of
atherogenesis (4). IMT increases if vascular walls are exposed
to cardiovascular risk factors such as age, serum low density
lipoprotein cholesterol, hypertension and smoking (5–16). A
reduction of cardiovascular risk factors inhibits IMT progres-
sion (17–20). Because B-mode ultrasound imaging of arterial
walls is a noninvasive and “patient-friendly” technique, it
allows for repeated measurements through time in larger
groups of patients. The method has therefore become a
powerful tool in studies of atherosclerosis.
In the Regression Growth Evaluation Statin Study (RE-
GRESS) (21), primarily the effect of 2 years of pravastatin
treatment on the evolution of the coronary lumen was studied
From the *Interuniversity Cardiology Institute, Utrecht; †Amsterdam Vas-
cular Medicine Group, Academic Medical Centre, Amsterdam; ‡Department of
Cardiology and Department of Medical Statistics, Leiden University Medical
Centre, Leiden; §Department of Radiology and Department of Clinical Neuro-
physiology, St. Antonius Hospital, Nieuwegein; and \Thorax Centre, Erasmus
University, Rotterdam, The Netherlands. ¶A complete list of REGRESS partic-
ipants appears in reference 21. The REGRESS trial was sponsored by Bristol-
Myers Squibb Company, Princeton, New Jersey.
Manuscript received April 26, 1997; revised manuscript received February
26, 1998, accepted March 5, 1998.
Address for correspondence: Dr. Eric de Groot, Interuniversity Cardiology
Institute, P.O. Box 19258, 3501 DG Utrecht, The Netherlands.
JACC Vol. 31, No. 7
June 1998:1561–7
1561
©1998 by the American College of Cardiology 0735-1097/98/$19.00
Published by Elsevier Science Inc. PII S0735-1097(98)00170-3
in a randomized fashion. In the B-mode ultrasound substudy of
REGRESS, the pravastatin treatment effects on carotid and
femoral artery walls were investigated. The studies in the two
different vascular beds allowed us to compare the state and
changes over time in the coronary lumen with the state and
changes over time in the peripheral arterial walls.
Methods
Study design and patient selection. REGRESS was de-
signed as a double-blind, placebo-controlled, multicenter study
to assess the 2-year treatment effects of a fixed daily dosage of
40 mg of the 3-hydroxy-3-methyl-glutaryl coenzyme A reduc-
tase inhibitor, pravastatin, on progression of coronary athero-
sclerosis as determined by quantitative coronary arteriography
(QCA). Eligible for the study were symptomatic men ,70
years of age with a serum cholesterol level between 4.0 and
8.0 mmol/liter (155 and 310 mg/dl) and a serum triglyceride
level #4.0 mmol/liter (354 mg/dl). The coronary angiogram
had to show a $50% diameter reduction in at least one major
coronary artery and had to be of sufficient quality for QCA
assessment. In 11 participating hospitals, 885 subjects were
included. The primary end points of the study were 1) change
in average mean segment diameter (MSD) per subject; and 2)
change in average minimal obstruction diameter (MOD) per
subject. The study was done under the auspices of the Inter-
university Cardiology Institute, The Netherlands. The coro-
nary angiographic part of the study has been reported previ-
ously (21).
B-mode ultrasound study objectives and end points. In
three REGRESS study centers (St. Antonius Hospital of
Nieuwegein and the University Hospitals of Groningen and
Nijmegen), subjects participated in B-mode ultrasound studies
of carotid and femoral artery walls. Written informed consent
was obtained from all subjects. The study was approved by the
Institutional Ethics Committees.
The primary end point of the B-mode ultrasound study was
the difference in change over time of the mean values of the
IMTs of the combined arterial wall segments. Secondary end
points included separate analyses of IMT measurement vari-
ables, analyses of the combined arterial near wall data, analyses
of the combined arterial far wall data and analyses of the data
of the separate arterial wall segments. In addition, the corre-
lations between peripheral IMT measurements and coronary
lumen diameters were assessed.
B-mode ultrasound imaging, off-line video image analysis
and quality control. B-mode ultrasound scans were done at
0 (baseline), 6, 12, 18 and 24 months. Scans were performed by
four sonographers. Two similarly calibrated ultrasound ma-
chines were used (ACUSON 128 and ACUSON 128XP sys-
tems equipped with L7384 7.0-MHz linear array transducers,
ACUSON Corporation).
The scans were done as follows. Subjects lay in the supine
position. Right and left carotid arteries were imaged from a
fixed lateral transducer angle. The left femoral arteries were
imaged from a fixed anterior transducer angle. The right
femoral artery segments were not imaged, because these were
the arteries where the catheters for the coronary arteriographic
assessments were introduced. Carotid and femoral artery wall
segments were defined by landmarks as represented in the
B-mode ultrasound image of the individual subject. The arte-
rial segment 1 cm proximal to the carotid dilation was defined
as the CCA segment. The carotid bulb was defined as the
arterial segment between the carotid dilation and carotid flow
divider. A 1-cm long arterial segment distal to the flow divider
was defined as the internal carotid artery (ICA) segment. A
1-cm long arterial segment proximal to the femoral dilation
was defined as the common femoral artery (CFA) segment.
The 1-cm arterial segment distal to the femoral flow divider
was defined as the superficial femoral artery (SFA) segment.
Of each arterial wall segment, 5-s real-time image sequences
were stored on S-VHS tape.
B-mode ultrasound video images were analyzed off-line
(S-VHS Panasonic NV-FS 100 HQ; VCR; Sony GVM-1400
QM multisync monitor; IDEN IVT-7P time base correctors,
IPC 80386 personal computers equipped with DT2861 and
DT2862 frame grabbers [Data Translation Inc.]). Image anal-
ysis software was developed in cooperation with Selzer et al.
(22). IMT variables are given in Figure 1.
In a continuous quality-control program before and
throughout the study, the contribution of measurement vari-
ability of sonographers, image analysts and instrumentation to
the total variability in the study group was investigated at
regular intervals (23,24).
Statistical analysis. Baseline characteristics of the treat-
ment groups were compared using the Student t test or
chi-square test as appropriate. The lipid observations were
analyzed using mixed-model analysis of variance for repeated
measures under the assumption of a compound symmetry
covariance structure. These were compared by using the
log-rank test. The IMT analyses were modeled using analysis
of variance with a random patient factor, fixed segment and
therapy factors. Time since start of therapy was modeled as a
linear covariate (25).
In the primary analyses the mean IMT variable was used
because in repeatability studies it showed the lowest measure-
ment variability (24). The sensitivity of IMT variables to
describe atherosclerotic change was investigated; analyses of
Abbreviations and Acronyms
CAD 5 coronary artery disease
CCA 5 common carotid artery
CFA 5 common femoral artery
CI 5 confidence interval
IMT 5 intima-media thickness
QCA 5 quantitative coronary arteriography
MOD 5 minimal (coronary) obstruction diameter
MSD 5 mean (coronary) segment diameter
REGRESS 5 Regression Growth Evaluation Statin Study
SFA 5 superficial femoral artery
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the IMT data of the combined near wall, of the combined far
wall and of each of the arterial wall segments were done for
mean and maximal IMT measurements. Relations between the
peripheral arterial segment IMTs were described by the Pear-
son correlation coefficient.
To calculate correlations between coronary arteriographic
and ultrasound data, baseline and follow-up mean percent
coronary obstruction scores were determined as follows: for
each patient the most severe narrowing, expressed as percent
lumen diameter reduction, was determined for each analyzable
coronary segment; the percentages were summed and the total
was divided by the number of contributing segments.
The relations between IMTs and mean percent coronary
stenoses were described by the Spearman correlation coeffi-
cient.
A p value # 0.05 was considered statistically significant. In
the arterial wall segment analyses, the Bonferroni correction
was applied. SPSS, BMDP (5V) and EGRET statistical pack-
ages were used.
Results
In the ultrasound studies 124 subjects were randomized to
receive placebo and 131 subjects were randomized to receive
active treatment. There were no major differences in clinical
variables and study comedication between the randomization
groups. Major clinical baseline data are reported in Table 1.
Pravastatin treatment effect on serum lipid values. Prava-
statin treatment significantly reduced total cholesterol, low
density lipoprotein cholesterol and triglycerides and raised
high density lipoprotein cholesterol. The maximal effect of
pravastatin on lipid values was apparent after 2 months and
remained more or less constant afterward. In the placebo
group the lipid values remained constant throughout the study.
Baseline and intreatment lipid values are reported in Table 2.
Clinical events. In the 255-subject ultrasound study group,
38 (14.9%) experienced a total of 46 predefined clinical events.
After 2 years of treatment, 79.8% (95% confidence interval
[CI] 72% to 88%) of the subjects in the placebo group were
without clinical events, whereas 90.1% (95% CI 85% to 95%)
of the subjects in the pravastatin group were without clinical
events (p 5 0.02). These percentages were similar to those of
the REGRESS study group as a whole (79% and 89%,
respectively) and did not vary among hospitals (p 5 0.52) (21).
B-mode ultrasound findings. B-mode ultrasound data
were available in 254 of the 255 subjects. This amounted to
12,241 arterial wall thickness measurements. Average (6SD)
baseline mean IMT was 0.86 6 0.33 mm (range 0.29 to 3.24).
Figure 1. B-mode ultrasound image analysis. Top, Interfaces are
identified with cross-marks. In the near wall, cross-marks identify the
trailing edge of the undefined (peri)adventitial-media interface (1) and
the gain-dependent trailing edge of the intima-lumen interface (2). In
the far wall, the cross-marks identify the well defined leading edges of
the lumen-intima interface (3) and media-adventitia interface (4).
Middle, Analysis software connects the cross-marks (far wall measure-
ment only shown). Bottom, Mean IMT is defined as d1 1 d2 1 z z z dn/n.
Maximal IMT is defined as the maximal delta between the two lines.
The length of the measurement along the arterial wall is kept as close
to 1 cm as possible, but is prone to differ between sites and patients
owing to individual anatomy and interference in the ultrasound image.
Table 1. Demographic Data
Placebo Group
(n 5 124)
Pravastatin Group
(n 5 131)
p
Value*
Age (years) 55.2 6 7.7 56.8 6 8.1 0.10
BMI (kg/m2) 26.4 6 2.8 26.1 6 2.7 0.27
SBP (mm Hg) 137.1 6 17.7 133.8 6 17.3 0.13
DBP (mm Hg) 82.2 6 11.3 79.6 6 10.0 0.06
Hypertension 39 (32%) 28 (21%) 0.07
Familial heart disease 65 (52%) 63 (48%) 0.49
Smoking history 111 (90%) 119 (91%) 0.72
Smoking at randomization 37 (30%) 43 (33%) 0.61
Smoking during study 39 (32%) 43 (33%) 0.81
Previous myocardial infarction 58 (47%) 73 (56%) 0.15
Mean IMT (mm)
n 1 f 0.86 6 0.32 0.87 6 0.34 0.91
n 0.82 6 0.31 0.83 6 0.32 0.92
f 0.88 6 0.32 0.89 6 0.35 0.99
Maximal IMT (mm)
n 1 f 1.07 6 0.41 1.08 6 0.45 0.78
n 1.01 6 0.39 1.03 6 0.42 0.97
f 1.10 6 0.42 1.10 6 0.47 0.82
*Significance level obtained from the Student unpaired t test or chi-square
test. Data presented are mean value 6 SD or number (%) of patients. BMI 5
body mass index; DBP 5 diastolic blood pressure; IMT 5 intima-media
thickness; n 5 near wall; f 5 far wall; SBP 5 systolic blood pressure.
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Baseline IMT data are included in Table 1. The combined
mean IMT data showed a highly significant pravastatin treat-
ment effect: IMT decreased 0.05 6 0.20 (SE) mm in the
pravastatin group, whereas the IMT in the placebo group
remained unchanged (p 5 0.0085). Analyses of the maximal
IMT data showed similar results. Average (6SD) baseline
maximal IMT was 1.07 6 0.43 mm (range 0.46 to 3.28). IMT
decreased 0.05 6 0.22 (SE) mm in the pravastatin group, but
increased 0.01 6 0.21 mm in the placebo group (p 5 0.0024).
Near wall data and far wall data were analyzed separately. In
254 subjects 5,122 near wall arterial segments and 7,119 far wall
arterial segments were measured. With respect to the near wall
mean IMT data, no effect of pravastatin was noticed (p 5
0.89). The far wall mean IMT data showed a highly significant
treatment effect (p , 0.0001) (Table 3). Therefore, the prav-
astatin treatment effect on the combined near and far wall
arterial segments was practically entirely accounted for by the
differential change in far wall IMT. Analyses of the separate
arterial wall segments revealed that a major pravastatin effect
was seen in the CFA far wall arterial segment: the placebo
group showed an IMT increase of 0.13 6 0.05 (SE) mm,
whereas in the pravastatin group showed a decrease of 0.06 6
0.05 mm in mean IMT (p 5 0.004) (Table 4 and Fig. 2).
Analyses of the maximal IMT data in the CFA far wall segment
showed similar results: no treatment effect was observed in the
near wall (p 5 0.83); in the far wall, IMT decreased 0.12 6 0.05
(SE) mm more in the pravastatin group than in the placebo
group (p , 0.0001).
Correlations in peripheral and coronary arteries. Periph-
eral arterial IMT measurements within subjects. The observed
intrapatient Pearson correlation coefficients of the peripheral
arterial wall segments varied between 20.17 and 0.81, with a
mean intraclass correlation of 0.20.
Baseline peripheral IMT measurements and coronary artery
stenosis. The combined baseline maximal IMT correlated with
the baseline MSD (r 5 20.32, p 5 0.001) and MOD (r 5
20.27, p 5 0.005). The Spearman correlation coefficients
between the baseline IMTs of the separate arterial wall
segment measurements and the baseline percent coronary
lumen stenosis varied from 0.23 to 0.36. It appeared that the
IMT measurements of the far wall CFA and of the far wall
SFA segments correlated moderately positively with the per-
cent coronary stenosis (p 5 0.33 and p 5 0.36, respectively;
both p , 0.01).
Pravastatin treatment effect between IMT measurements and
coronary artery stenosis. In the REGRESS study complete sets
of repeated QCA data on 653 subjects were available. Analyses
of the two primary coronary end points—differences between
the mean values of the MSD and the median values of the
MOD—showed a significant pravastatin treatment effect
(dMSD 0.04 mm, p 5 0.02; dMOD 0.06 mm, p 5 0.001) (21).
The analysis of the QCA data of the 255 subjects who
participated in the B-mode ultrasound study showed a similar,
statistically nonsignificant trend in the change of coronary
lumen diameter (dMSD 0.02 mm, p 5 0.43; dMOD 0.03 mm,
p 5 0.23).
There were no significant correlations between the change
in the mean percent coronary stenosis (nor in any of the other
variables of coronary diameter change) and change in IMT in
any of the arterial wall segments (all p . 0.30).
Discussion
In the REGRESS B-mode ultrasound study pravastatin
treatment effect on combined carotid and femoral artery IMT
were highly significant. The participants of the ultrasound
study received coronary arteriograms, as did all REGRESS
patients. The correlations between peripheral wall thickness
and coronary lumen measurements were low to moderate, and
no correlations in treatment effects between the two vascular
beds were observed.
Table 3. Pravastatin Treatment Effects in the REGRESS B-Mode
Ultrasound Study Group (n 5 255): Change in Coronary Lumen
and Peripheral Intima-Media Thickness
Placebo
Group
Pravastatin
Group p Value*
Coronary lumen variables
MSD (mm) 0.06 6 0.16 0.04 6 0.15 0.43
MOD (mm) 0.08 6 0.18 0.05 6 0.24 0.23
%S 0.9 6 5.4 1.2 6 5.9 0.76
Peripheral IMT (mm)
Mean 0.00 6 0.20 0.05 6 0.20 0.0085
(n: 0.89; f: , 0.0001)
Maximal 20.01 6 0.21 0.05 6 0.22 0.0024
(n: 0.83; f: , 0.0001)
*Significance level obtained from the Student t test; p , 0.05 considered
significant. Change is defined as baseline value minus value of variables after 2
years (positive values indicate an increase in coronary lumen and a decrease in
wall thickness). Data presented are mean value 6 SE. MOD 5 minimal
(coronary) obstruction diameter; MSD 5 mean (coronary) segment diameter;
%S 5 mean percent stenosis (mean values of per patient percent lumen
reduction of analyzable segments divided by number of contributing segments);
other abbreviations as in Table 1.
Table 2. Baseline and Treatment Lipid Values
Placebo Group
(n 5 124)
Pravastatin Group
(n 5 131)
p
Value*
Total cholesterol (mmol/liter)
Baseline 6.12 6 0.88 6.18 6 0.88 0.58
Follow-up 6.14 6 0.98 4.92 6 1.07 , 0.001
HDL cholesterol (mmol/liter)
Baseline 0.97 6 0.22 0.99 6 0.25 0.41
Follow-up 0.95 6 0.22 1.05 6 0.25 , 0.001
LDL cholesterol (mmol/liter)
Baseline 4.33 6 0.79 4.36 6 0.80 0.77
Follow-up 4.30 6 0.88 3.11 6 0.94 , 0.001
Triglycerides (mmol/liter)
Baseline 1.82 6 0.77 1.85 6 0.78 0.78
Follow-up 1.95 6 0.98 1.67 6 0.93 0.01
*Significance level obtained from the Student unpaired t test. Data presented
are mean value 6 SD. HDL 5 high density lipoprotein; LDL 5 low density
lipoprotein.
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Mean and maximal IMT as arterial wall thickness vari-
ables. Analyses of MEAN IMTs and maximal IMTs showed
similar results. Both IMT variables are suitable for use in
carotid and femoral artery wall thickness studies.
Near and far wall IMT measurements. The ultrasound
interfaces in the B-mode ultrasound image near and far walls
have different origins (as shown in Fig. 1). The distances
between the interfaces of the far wall represent the borders of
the intima-media complex; those of the near wall do not (25).
The value and validity of B-mode ultrasound arterial near wall
thickness measurements are therefore a topic of debate
(26 –28).
In this study we observed treatment effects in the far wall
segments only. This finding strongly suggests that in medical
intervention trials, where small differences in the progression
of the intima-media complex are observed, far wall IMT
measurements are more sensitive than near wall thickness
measurements in detecting change.
For epidemiologic purposes it is suggested to include near
wall measurements at baseline of a clinical trial and to proceed
solely with far wall measurements in follow-up.
Finding a major treatment effect in the far wall of the CFA.
Analyses of the IMT data of the separate arterial wall seg-
ments showed a highly significant treatment effect on the far
wall of the CFA. A reason for this finding may be that the
highest maximal IMT (1.37 mm) and the highest standard
deviation (0.69 mm) were observed in this arterial wall seg-
ment (baseline data). The high standard deviation may indi-
cate a high prevalence of arterial wall irregularities. It may be
hypothesized that a pronounced treatment effect in this arterial
wall segment was observed because arterial walls with a high
incidence of lesions have a higher arterial wall thickness
progression rate. As a fast progressor, the CFA far wall may be
more sensitive to low density lipoprotein cholesterol and
triglyceride reduction. A treatment effect in the far wall of the
CFA may therefore be more readily observed (18,20).
Comparison with other studies. In several atherosclerosis
regression studies, B-mode ultrasound imaging has been used
for investigation and demonstration of treatment effects of
cholesterol reduction. The 4-year Cholesterol Lowering Ath-
erosclerosis Study (CLAS) tested the treatment effects of
colestipol-niacin plus diet therapy in 46 nonsmoking men with
previous coronary bypass surgery (19). B-mode ultrasound
scans were done in four carotid artery far wall segments. There
were significant treatment effects after 2 and 4 years (p ,
0.0001). The Asymptomatic Carotid Artery Progression Study
(ACAPS) was a 3-year trial in which the treatment effect of a
daily dosage of 20 to 40 mg of lovastatin, in a factorial design
with warfarin or placebo, or both, was investigated (17). In this
trial, 12 (near and far) carotid artery wall segments were
scanned in asymptomatic men and women with early carotid
atherosclerosis (as assessed with B-mode ultrasound imaging).
Table 4. Pravastatin Treatment Effect on Carotid and Femoral Artery Intima-Media Thickness
Arterial Wall
Segments
Near Wall Far Wall
Placebo Pravastatin p Value* Placebo Pravastatin p Value
CCA
Right 0.02 6 0.02 0.00 6 0.02 0.40 0.02 6 0.02 20.01 6 0.02 0.35
Left 0.00 6 0.02 0.00 6 0.02 0.88 0.05 6 0.02 0.04 6 0.02 0.67
CB
Right 0.15 6 0.06 0.21 6 0.06 0.47 0.09 6 0.04 0.06 6 0.04 0.62
Left 0.11 6 0.05 0.09 6 0.05 0.73 0.08 6 0.04 0.01 6 0.04 0.23
ICA
Right 20.10 6 0.08 20.06 6 0.07 0.62 20.07 6 0.05 20.06 6 0.04 0.92
Left 20.07 6 0.07 0.06 6 0.06 0.12 20.06 6 0.04 0.01 6 0.04 0.23
CFA, left 0.01 6 0.04 0.05 6 0.04 0.49 20.13 6 0.05 0.06 6 0.05 0.004
SFA, left 0.04 6 0.03 0.04 6 0.03 0.94 0.04 6 0.02 0.01 6 0.02 0.40
*Significance level obtained from the Student t test; p , 0.005 considered significant. Change is defined as baseline
intima-media thickness minus that after 2 years (positive values indicate a decrease in intima-media thickness in
millimeters). Data presented are mean value 6 SE. CB 5 carotid bulb; CCA 5 common carotid artery; CFA 5 common
femoral artery; ICA 5 internal carotid artery; SFA 5 superficial femoral artery.
Figure 2. Change in CFA far wall IMT in millimeters (6SE) for the
placebo and pravastatin groups after a treatment period of 2 years.
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A lovastatin treatment effect on the combined maximal IMT
was observed (p , 0.001). Pravastatin treatment effects on
peripheral IMT have been described in the B-mode ultrasound
components of the Pravastatin, Lipids, and Atherosclerosis in
the Carotid arteries trial (PLAC-2) (29,30) and Kuopio Ath-
erosclerosis Prevention Study (KAPS) (20). In the 3-year
PLAC-2 trial, 151 men and women with coronary artery
disease (CAD), diet-resistant elevated low density lipoprotein
cholesterol and the presence of at least one carotid lesion were
randomized to receive placebo or 20 to 40 mg of pravastatin
daily. The primary outcome measure—that is, the change in
the mean value of the maximal IMT measurements over time
in 12 carotid (near and far wall) arterial segments, was not
significantly different between the placebo and treatment
group (p 5 0.44). However, a subanalysis of the separate
arterial segments showed a significant treatment effect in the
CCA (p 5 0.03). KAPS investigated the 3-year treatment effect
of a daily dosage of 40 mg of pravastatin in 447 hypercholes-
terolemic men (low density lipoprotein cholesterol .4.0 mmol/
liter) using six carotid and femoral artery far wall segments.
The treatment effect for the combined segment IMT was
significant (p 5 0.02).
Comparison in the interpretation of the results of this
substudy and the overall REGRESS B-mode ultrasound study
may be difficult because study group selection, study duration,
scanning and off-line video image analysis procedures and
statistical analyses differ for each of the studies. In all of the
aforementioned studies, different approaches to the different
methodologic components were used. However, whatever
methodology was chosen, the common denominator for all of
these studies was demonstration of treatment effects in periph-
eral arterial walls. The REGRESS B-mode ultrasound study
has some distinctly different characteristics when compared
with the aforementioned studies. The study group was selected
based on the presence of proven CAD and not on risk factors.
Also, no attempt was made to select the B-mode ultrasound
study group based on increased cardiovascular risk factors or
increased IMT.
Others have investigated correlations between peripheral
and coronary atherosclerosis (29,31,32). In our study a univar-
iate approach was taken because it most closely describes the
ability of peripheral B-mode ultrasound IMT measurements to
predict coronary atherosclerosis in screening procedures. Our
results of this approach are in agreement with those of Adams
et al. (31). Multivariate correlation models were described by
Adams et al. (31), Craven et al. (32), and Crouse et al. (29).
These last three models add little to the predictive value of
IMT for patients with CAD.
Potential and limitations of B-mode ultrasound atheroscle-
rotic studies. From epidemiologic studies it is known that
increased IMT is positively related to atherosclerotic risk
factors and CAD (6,8–10,12,17,28). In lipid intervention stud-
ies treatment effects were shown in peripheral arteries
(19,20,29,30) and coronary arteries (21,33,34). In this study
pravastatin treatment effects were shown on peripheral and
coronary arteries.
Ideally, one would like to individually predict the status and
treatment effects in the coronary arteries by means of nonin-
vasive peripheral B-mode ultrasound imaging of peripheral
arterial walls. However, because our studies showed treatment
effects in the study group as a whole but not on an individual
basis, and also lacked correlation between peripheral and
coronary measurements, this is not a goal likely to be achieved.
Several reasons for the low correlations can be mentioned.
First, there is a great variability in the manifestation of
atherosclerosis within and between vascular beds (18,31). The
general association between sites is in agreement with the
systemic nature of atherosclerosis, whereas the lack of tight
agreement between the sites is an expression of the focal
nature of the atherosclerotic lesion formation. Second, 7-MHz
B-mode ultrasound imaging has a relatively low axial resolu-
tion (0.3 to 0.4 mm) (1,12,13,29) in comparison with the size of
the intima-media complex (0.6 to 1.4 mm) and the treatment
effect of statins (0.05 to 0.1 mm). Third, B-mode ultrasound
can image the full range of atherogenesis in arterial walls. In
contrast, coronary arteriography focuses on plaques through
visualization of the arterial lumen (29), which results in an
underestimation of the extent of (especially early) atheroscle-
rosis.
Therefore, even if the resolution of B-mode ultrasound
imaging and coronary angiography were enhanced, the vari-
ability of the genesis of atherosclerotic lesion formation
(31,35,36) throughout the different sites of the vascular beds is
such that a peripheral observation of an arterial wall is unable
to predict coronary lumen stenosis. As a consequence, within
the individual, an IMT measurement of a given peripheral
arterial wall segment cannot be used to predict the state of
atherosclerosis in the coronary arteries, let alone the predic-
tion of even smaller individual treatment effects.
Clinical implications. The findings of this study are evi-
dence of the important contribution of statin treatment to the
reduction of cardiovascular risk factors.
Conclusions. Our results confirm that pravastatin therapy
inhibits the progression of peripheral atherosclerosis. In that
sense, peripheral arteries and coronary arteries showed paral-
lel trends.
The low correlation of the state and evolution of athero-
sclerosis between peripheral arterial wall thickness measure-
ments and coronary artery lumen measurements reflect the
great morphologic variety of atherosclerosis within and be-
tween vascular beds within and between individuals. Conse-
quently, peripheral arterial wall thickness measurements are
unsuitable as a screening tool for CAD or as a test for
individual medication treatment effects on coronary arteries.
The B-mode ultrasound study showed highly significant
pravastatin treatment effects. Indeed, B-mode ultrasound im-
aging was more sensitive than QCA in detecting treatment
effects. Therefore, B-mode ultrasound measurements of the
carotid and femoral artery intima-media complex are highly
suitable to assess the antiatherosclerotic properties of agents.
1566 DE GROOT ET AL. JACC Vol. 31, No. 7
PRAVASTATIN AND PERIPHERAL ATHEROSCLEROSIS June 1998:1561–7
References
1. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial
thickness of the arterial wall: a direct measurement with ultrasound imaging.
Circulation 1986;74:1399–1406.
2. Poli A, Tremoli E, Colombo A, Sirtori M, Pignoli P, Paoletti R. Ultrasono-
graphic measurement of the common carotid artery wall thickness in
hypercholesterolemic patients: a new model for the quantitation and
follow-up of preclinical atherosclerosis. Atherosclerosis 1988;70:253–61.
3. Linssen FMA. Non-invasive arterial wall tissue characterization: develop-
ment and evaluation of narrowband ultrasound techniques [dissertation].
Maastricht, The Netherlands: University of Maastricht, 1992:32–45.
4. Bots ML, Mulder PGH, Hofman A, van Es GA, Grobbee DE. Assessment
of early atherosclerosis: a new perspective. J Drug Res 1991;16:150–4.
5. Howard G, Sharrett AR, Heiss G, et al. Carotid artery intimal-medial
thickness distribution in general populations as evaluated by B-mode
ultrasound. Stroke 1993;24:1297–1304.
6. Bots ML, Mulder PGH, van Es GA, Grobbee DE. Cardiovascular determi-
nants of carotid artery disease: the Rotterdam Study. Hypertension 1992;19:
717–20.
7. Bots ML, van Swieten JC, Breteler MM, et al. Cerebral white matter lesions
and atherosclerosis in the Rotterdam Study. Lancet 1993;341:1232–7.
8. Heiss G, Sharrett AR, Barnes R, Chambless LE, Szklo M, Alzola C. Carotid
atherosclerosis measured by B-mode ultrasound in populations: associations
with cardiovascular risk factors in the ARIC study. Am J Epidemiol
1991;134:250–6.
9. O’Leary DH, Polak JF, Wolfson SK, et al., on behalf of the CHS Collabo-
rative Research Group. Use of sonography to evaluate carotid atheroscle-
rosis in the elderly: the cardiovascular health study. Stroke 1991;22:1155–63.
10. Salonen R, Salonen JT. Determinants of carotid intima-media thickness: a
population based ultrasonography study in Eastern Finnish men. J Intern
Med 1991;229:225–31.
11. Salonen R, Salonen JT. Progression of carotid atherosclerosis and its
determinants: a population based study. Atherosclerosis 1990;81:33–40.
12. Salonen R, Salonen JT. Ultrasonographically assessed carotid morphology
and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol
1991;11:1245–9.
13. Wendelhag I, Wiklund O, Wikstrand J. Arterial wall thickness in familial
hypercholesterolemia: ultrasound of intima-media thickness in the common
carotid artery. Arterioscler Thromb Vasc Biol 1992;12:70–7.
14. Wendelhag I, Wiklund O, Wikstrand J. Atherosclerotic changes in the
femoral and the carotid arteries in familial hypercholesterolemia. Arterio-
scler Thromb Vasc Biol 1993;13:1404–11.
15. Tell GS, Howard G, McKinney WM, Toole JL. Cigarette smoking and
extracranial carotid atherosclerosis. JAMA 1989;261:1178–80.
16. Gnasso A, Pujia A, Irace C, Mattioli PL. Increased carotid arterial wall
thickness in common hyperlipidemia. Coron Artery Dis 1995;6:57–63.
17. Furburg CD, Adams HP, Applegate WB, et al. Effect of lovastatin on early
atherosclerosis and cardiovascular events. Circulation 1994;90:1679–87.
18. Blankenhorn DH, Nodis HN. Arterial imaging and atherosclerosis reversal.
Arterioscler Thromb Vasc Biol 1994;14:177–92.
19. Blankenhorn DH, Selzer RS, Crawford DW, et al. Beneficial effects of
colestipol therapy on the common carotid artery. Circulation 1993;88:20–8.
20. Salonen R, Nyyssonen K, Porkkla E, et al., for the Kuopio Atherosclerosis
Prevention Study (KAPS). A population-based primary preventive trial of
the effect of LDL lowering on atherosclerotic progression in carotid and
femoral arteries. Circulation 1995;92:1758–64.
21. Jukema JW, Bruschke AVG, van Boven AJ, et al., on behalf of the
REGRESS Study Group. Effects of lipid lowering by pravastatin on progres-
sion and regression of coronary artery disease in symptomatic men with
normal to moderately elevated serum cholesterol levels: the Regression
Growth Evaluation Statin Study (REGRESS). Circulation 1995;91:2528–40.
22. Selzer RS, Hodis HN, Kwong-Fu H, et al. Evaluation of computerised edge
tracking for quantifying intima-media thickness of the common carotid
artery from B-mode ultrasound images. Atherosclerosis 1994;111:1–11.
23. Bond MG, Barnes RW, Riley WA, et al. High resolution B-mode ultrasound
scanning methods in the Atherosclerosis Risk in Communities Study
(ARIC). J Neuroimaging 1991;1:68–73.
24. De Groot E, Zwinderman AH, Van der Steen AFW, et al. Variance
components analysis of carotid and femoral intima-media thickness mea-
surements. Ultrasound Med Biol. In press.
25. Espeland MA, Byington RP, Hire D, Davis VG, Hartwell T, Probstfield J.
Analysis strategies for serial multivariate ultrasonographic data that are
incomplete. Stat Med 1992;11:1041–56.
26. Wong M, Edelstein J, Wollman J, Bond MG. Ultrasonic pathological
comparison of the human arterial wall: verification of intima-media thick-
ness. Arterioscler Thromb Vasc Biol 1993;13:482–6.
27. Montauban van Swijndregt AD, The SHK, Gussenhoven EJ, et al. An in
vitro evaluation of the line pattern of the near and the far walls of carotid
arteries using B-mode ultrasound. Ultrasound Med Biol 1996;22:1007–15.
28. Crouse JR, Craven TE, Hagaman AP, Bond MG. Association of coronary
disease with segment-specific intimal-medial thickening of the extracranial
carotid artery. Circulation 1995;92:1141–7.
29. Crouse JR, Byington PB, Bond MG, et al. Pravastatin, lipids, and athero-
sclerosis in the carotid arteries (PLAC-II). Am J Cardiol 1995;75:455–9.
30. Byington PB, Furberg CD, Crouse JR, Espeland MA, Bond MG. Pravasta-
tin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J
Cardiol 1995;76:54C–59C.
31. Adams MR, Nakagomi A, Keech A, et al. Carotid intima-media thickness is
only weakly related with the extent and severity of coronary artery disease.
Circulation 1995;92:2127–34.
32. Craven TE, Ryu JE, Espeland MA, et al. Evaluation of the associations
between carotid artery atherosclerosis and coronary artery stenosis: a case
control study. Circulation 1990;82:1230–42.
33. Blankenhorn DH, Azen SP, Kramsch DM, et al., and the MARS Research
Group. The Monitored Atherosclerosis Regression Study (MARS): coro-
nary angiographic changes with lovastatin therapy. Ann Intern Med 1993;
119:969–76.
34. Waters D, Higginson L, Gladstone P, et al., and the CCAIT Study Group.
Effect of monotherapy with an HMG Co-A reductase inhibitor on the
progression of coronary atherosclerosis as assessed by serial quantitative
arteriography: the Canadian Coronary Atherosclerosis Intervention Trial.
Circulation 1994;89:959–68.
35. Bruschke AVG, Kramer JR, Bal ET, Ul Haque I, Detrano RC, Goormastic
M. The dynamics of progression of coronary atherosclerosis in 168 medically
treated patients who underwent coronary arteriography three times. Am
Heart J 1989;117:296–305.
36. Stone PH, Gibson CM, Pasternak RC, et al. Natural history of coronary
atherosclerosis using quantitative angiography in men, and implications for
clinical trials of coronary regression. Am J Cardiol 1993;71:766–72.
1567JACC Vol. 31, No. 7 DE GROOT ET AL.
June 1998:1561–7 PRAVASTATIN AND PERIPHERAL ATHEROSCLEROSIS
